58 results about "Oligodendroglia Cell" patented technology

The present invention concerns the use of a population of cells comprising: (a) neural precursor cells committed to an oligodendroglial fate; (b) uncommitted neural precursor cells (c) differentiated oligodendrocytes; or (d) a combination of any one of (a) to (c) for the treatment of CNS autoimmune diseases, or for the preparation of a pharmaceutical composition for treating CNS autoimmune diseases, the population of cells being derived from human pluripotent stem cells. The invention also provides methods for obtaining such populations of cells, namely, neural precursor cells committed to an oligodendroglial fate as well as differentiated oligodendrocytes which then can be used in the treatment of CNS autoimmune diseases. A preferred autoimmune disease in the context of the present invention is multiple sclerosis where the population of cells is administered to the CNS for local treatment of the disease.

The invention provides a method for separating and subculturing the primary neural stem cell of the human embryo midbrain. The method is used for separating, culturing and differentiating the primary neural stem cell of the human embryo midbrain in vitro by separating, culturing and identifying the neural stem cell of the human embryo midbrain. The method comprises the following steps: separating and culturing the primary neural stem cell of the human embryo midbrain, subculturing the primary cell, carrying out induced differentiation on the cell, carrying out immunocytochemical staining, and counting the number of cells. According to the method, a neural stem cell is separated from human embryo midbrain successfully by adopting the serum-free culturing and single-cell cloning technology, and the neural stem cell is cultured, subcultured and subjected to adherent differentiation observation, wherein the cell has the continuous cloning capacity and can subculture and express the neural nidogen antigen. The differentiated cell can express the specific antigens of the neuron cells, the colloid cells and oligodendroglia cells.

The invention discloses a method for preparing tissue engineering spinal cords by using mesenchymal stem cells derived from dermis, which comprises the following steps of 1) separating dMSCs, and carrying out passage on the dMSCs so as to obtain dMSCs primary cells; 2) moving the dMSCs primary cells obtained through separating to an amplification culture medium so as to carry out amplification; and 3) dropwise adding an engineering spinal cord saturated water solution into a physiological saline solution containing deep nerve nutriments, retinoic acid and Neuregulin, standing the obtained mixture, carrying out gradient alcohol dehydration on the mixture, and carrying out vacuum drying on the mixture; and infecting the dMSCs subjected to amplification by using a brain-derived neurenergen adenovirus expression vector, and inoculating cells to an engineering spinal cord material for culturing. In the method, tissue engineering spinal cords can effectively promote cell proliferation; and the differentiation rates of the tissue engineering spinal cords to nerve cells and oligodendroglia cells are respectively about 4.8% and 1.5% which are far higher than those of pure scaffold materials (the differentiation rates of pure scaffold materials to nerve cells and oligodendroglia cells are respectively 1.8% and 0.5%).

The invention relates to the technical field of biology, in particular to a method for differentiating human induced pluripotent stem cells into oligodendrocytes, a kit and application. The method comprises the step of culturing stem cells by using at least one of the following culture media of a nerve induction complete culture medium, an N2 culture medium, a B27 culture medium and an OPC mature culture medium, and more preferably, the number of the oligodendrocytes induced by using the puerarin-containing OPC mature culture medium can be increased by 30% compared with the number of the oligodendrocytes induced by not using puerarin.

This invention relates to methods of producing oligodendrocytes from multipotent neural stem cells by using at least one oligodendrocyte promoting factor, particularly granulocyte-macrophage colony stimulating factor, granulocyte colony stimulating factor, interleukin 3 or interleukin 5. The neural stem cells may optionally be expanded prior to being subjected to the oligodendrocyte promoting factor.

The invention relates to a recombinant vector used for expressing light-sensitive type adenylate cyclase, applications and a construction method of the recombinant vector, and a treating system for demyelination. The recombinant vector comprises a viral vector, and a shuttle plasmid wrapped in the viral vector and carrying the gene sequence of the light-sensitive type adenylate cyclase. The gene sequence of the light-sensitive type adenylate cyclase comprises specific promoters of an oligodendroglia cell and a Schwann cell. The recombinant vector is adopted to infect a demyelination part so that the gene sequence of the light-sensitive type adenylate cyclase is only expressed in the oligodendroglia cell and the Schwann cell. Under stimulation of light, the cAMP level in the two cells can be adjusted directionally, thus promoting remyelination and stable myelin sheath growth and achieving an objective of treatment of the demyelination by cell specificity.

The invention discloses a method for inducing human or animal somatic cells to neural stem cells and purpose of neural stem cells obtained by the method. By overexpression of transcription factor Ptf1a in separated human or animal somatic cells and culture in a culture medium containing EGF and bFGF, somatic cells can be induced to neural stem cells (iNSCs). The iNSCs obtained by the method has self-renewing capability, and can stably passage for 50 generations and above and maintain original cell characteristics. By culture in different in vitro differentiation mediums, the iNSCs can be efficiently differentiated to neurons, astrocytes and oligodendrocytes. By injecting the iNSCs in animal bodies, the injected cells can be integrated into nervous tissues of retina, cerebrum, etc. the method of the invention is simpler, safer and more efficient than previous methods. The iNSCs obtained by the method and further differentiated cells can be applied to cell models of nerve diseases, drug screening, stem cell treatment and the like.

The invention provides an RNA inhibitor and application thereof. The RNA inhibitor is an miRNA-17-5p inhibitor and has an miRNA-17-5p inhibition sequence. The miRNA-17-5p inhibitor can be used for inhibiting activation and proliferation of astrocytes after spinal cord injuries. According to the RNA inhibitor, oligodendrocytes after the spinal cord injuries are applied to generating a large quantity of exosomes carrying miR-17-5p, the exosomes can be taken in by the astrocytes, and thus activation characteristics of the astrocytes are promoted; and an antagonist of the miR-17-5p is designed, thus, a purpose of reducing astrocyte excessive proliferation is achieved, and an effective therapeutic target is provided for treating the spinal cord injuries.

The invention relates to the technical field of biological drug carrier preparation, and particularly discloses a targeting extracellular vesicle as well as a preparation method and application thereof. The method comprises the following steps: constructing an LV-Lc-PDGFA fusion expression lentiviral vector, infecting neural stem cells, constructing a stably transfected cell line NSC-LV-Lc-PDGFA, and positioning an expressed exogenous ligand PDGFA on the surface of an extracellular vesicle membrane, so that the targeting capability of the extracellular vesicles on the oligodendroglia lineage cells is improved. The extracellular vesicle with the membrane surface expressing the PDGFA small peptide has high targeting property, can be used as a drug carrier, and has a good treatment effect on demyelination diseases.

The invention belongs to the technical field of polypeptide chemistry and immunology, and particularly relates to a myelin oligodendrocyte glycoprotein antibody kit, which takes recombinant protein coded by an extracellular region sequence of a human myelin oligodendrocyte glycoprotein gene as a coating antigen. The invention also provides a detection method of the kit. The method comprises the following steps: separating to obtain an antigen-to-be-detected antibody-binding antigen-MOG enzyme conjugate compound, adding a color developing agent A and a color developing agent B, adding a stop solution, detecting by using a microplate reader, and calculating the concentration of MOG-Ab according to the absorbance OD value and a standard curve. According to the invention, the defects in the prior art are overcome,the myelin oligodendrocyte glycoprotein antibody in serum can be quickly and specifically detected, and the kit is good in reaction specificity, high in sensitivity, simple to operate, low in cost, stable and reliable in reaction result and easy to observe.

The invention provides a high-low density anchorage-dependent cell culturing method of old embryonic age neural stem cells. The method comprises the steps of: separation and culture of the cortex neural stem cells, culture of the neural stem cells by the high-low density anchorage-dependent cell culturing method, subculture of the neural stem cells, monoplast cloning of the neural stem cells, differentiation culture of the neural stem cells and detection by an immumofluorescence method. According to the method provided by the invention, self-renewal neural stem cells with the differentiative potential are separated and cultured from an embryonic human brain cortex which is 13 weeks old by serum-free culture and monoplast clone technology. A plenty of neural stem cells are cultured by the high-low density anchorage-dependent cell culturing method, wherein the density decreases gradually. The cells have the continuous cloning capacity, can be subcultured, and express neural nidogen antigen. Differentiated cells express the specific antigens of neuron, gliocyte and oligodendroglia cell, so that the problem that embryo neural stem cells are hard to culture is solved.

The invention relates to the field of antitumor drugs, and in particular relates to an application of quetiapine fumarate in preparing a medicine for treating glioma. Through in-vivo and in-vitro experiments, the effects of resisting glioma and glioma stem cells of quetiapine fumarate (KUI) and the effects obtained by mixing KUI with chemotherapy drug temozolomide (TMZ) are investigated; quetiapine fumarate can inhibit growth of glioma, and promote the glioma stem cells to express markers of oligodendroglia cells, and after being mixed with TMZ for application, quetiapine fumarate increases the sensitivity of the glioma cells for temozolomide, and the inbibiting effect is better; after temozolomide acts, quetiapine fumarate can delay the growth of recurrent glioma; quetiapine fumarate can promote the glioma stem cells to differentiate and mature towards the oligodendroglia like cells by taking the glioma stem cells as the action target. Therefore, quetiapine fumarate can be used for preparing the medicine for treating glioma, and achieves good effects for treating and prognosis of glioma.

The invention relates to synthetic modified Olig2mRNA and application thereof, and belongs to the technical field of stem cell induced differentiation. The protein translated by the Olig2mRNA is always in a dephosphorylation state. By transfecting neural precursor cells derived from human induced pluripotent stem cells, rapid and efficient directional differentiation of the human induced pluripotent stem cells to oligodendrocytes is realized, and the designed and modified Olig2mRNA shows higher efficiency of induced differentiation than wild type Olig2mRNA. By utilizing the method disclosed by the invention, the induced pluripotent stem cells can be quickly differentiated into the oligodendrocytes, the risk of gene integration of the oligodendrocytes induced based on overexpression of a transcription factor SOX10 in the past can be avoided, and the method is more beneficial to the development of clinical tests. The rapid induction of oligodendrocytes derived from the human induced pluripotent stem cells provides a technical support for treating myelin sheath injury type neurodegenerative diseases through transplantation of oligodendrocyte precursor cells in the future.

The invention discloses a method for preparing a tissue engineering spinal cord by using ancestral cells originated from skin. The method comprises the following steps: 1) separating SKPs, and passing to obtain SKPs primary cells; 2) immigrating the SKPs primary cells separated to an amplification culture medium for amplification; and 3) preparing the tissue engineering spinal cord, and dropwise adding saturated aqueous liquor of a tissue engineering spinal cord material to physiological saline liquor containing Neurotrophin-3(NT3), retinoic acid and Neuregulin; infecting the amplified SKPs by a brain-derived neurenergen adenovirus expression vector, and inoculating the cells to the tissue engineering spinal cord material to cultivate. In the method disclosed by the invention, the tissue engineering spinal cord can effectively promote cell proliferation, and the differentiating proportions of the tissue engineering spinal cord toward nerve cells and oligodendroglia cells are about 4.8% and 1.5% which are far greater than 1.8% and 0.5% of a pure support material.